3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
4
Sarcoma
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
Patients With Advanced or Metastatic Solid Tumors
1
PRETEXT I Hepatoblastoma
1
Neurofibromatosis 2
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Mesothelial
1
Mouth Neoplasms
1
Melanoma
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Erdheim-Chester Disease
1
Endometrial Adenocarcinoma
1
Endocrine Gland Neoplasms
1
Interventions
Paclitaxel
4
Cyclophosphamide
4
exemestane
3
Taxes
3
Tamoxifen
3
Letrozole
3
Doxorubicin
3
Anastrozole
3
Trastuzumab
2
Leuprolide
2
Immunotherapy
2
Goserelin
2
Carboplatin
2
trastuzumab biosimilar HLX02
1
ribociclib
1
pegfilgrastim
1
elacestrant
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
abemaciclib
1
Vitamins
1
Standard of Care
1
Radiosurgery
1
Psychiatric Rehabilitation
1
Practice Guidelines as Topic
1
PF-05280014
1
Ontruzant
1
Omeprazole
1
Ogivri
1
Neoadjuvant Therapy
1
Methods
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Breast Neoplasms, Male
×
temsirolimus
×
1 year
×
Clear all
No trials found.